FOLH1 and prostate cancer: In addition to this strategy, Leconet et al. have developed an injectable in situ biodegradable polymer-based protein delivery system to prolong the half-life and the antitumor efficacy of BiTEs targeting both prostate-specific membrane antigen (PSMA) and the CD3 T-cell receptor in prostate cancer [110].